Cargando…

Association between circulating alpha-1 antitrypsin polymers and lung and liver disease

BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 antitrypsin (AAT) protein within hepatocytes. The relevance of circulating polymers (CP) of AAT in the pathogenesis of lung...

Descripción completa

Detalles Bibliográficos
Autores principales: Núñez, Alexa, Belmonte, Irene, Miranda, Elena, Barrecheguren, Miriam, Farago, Georgina, Loeb, Eduardo, Pons, Mònica, Rodríguez-Frías, Francisco, Gabriel-Medina, Pablo, Rodríguez, Esther, Genescà, Joan, Miravitlles, Marc, Esquinas, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442448/
https://www.ncbi.nlm.nih.gov/pubmed/34526035
http://dx.doi.org/10.1186/s12931-021-01842-5
_version_ 1783753009972379648
author Núñez, Alexa
Belmonte, Irene
Miranda, Elena
Barrecheguren, Miriam
Farago, Georgina
Loeb, Eduardo
Pons, Mònica
Rodríguez-Frías, Francisco
Gabriel-Medina, Pablo
Rodríguez, Esther
Genescà, Joan
Miravitlles, Marc
Esquinas, Cristina
author_facet Núñez, Alexa
Belmonte, Irene
Miranda, Elena
Barrecheguren, Miriam
Farago, Georgina
Loeb, Eduardo
Pons, Mònica
Rodríguez-Frías, Francisco
Gabriel-Medina, Pablo
Rodríguez, Esther
Genescà, Joan
Miravitlles, Marc
Esquinas, Cristina
author_sort Núñez, Alexa
collection PubMed
description BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 antitrypsin (AAT) protein within hepatocytes. The relevance of circulating polymers (CP) of AAT in the pathogenesis of lung and liver disease is not completely understood. Therefore, the main objective of our study was to determine whether there is an association between the levels of CP of AAT and the severity of lung and liver disease. METHOD: This was a cross-sectional study in patients with different phenotypes of AATD and controls. To quantify CP, a sandwich ELISA was performed using the 2C1 monoclonal antibody against AAT polymers. Sociodemographic data, clinical characteristics, and liver and lung parameters were collected. RESULTS: A cohort of 70 patients was recruited: 32 Pi*ZZ (11 on augmentation therapy); 29 Z-heterozygous; 9 with other genotypes. CP were compared with a control group of 47 individuals (35 Pi*MM and 12 Pi*MS). ZZ patients had the highest concentrations of CP (p < 0.001) followed by Z heterozygous. The control group and patients with Pi*SS and Pi*SI had the lowest CP concentrations. Pi*ZZ also had higher levels of liver stiffness measurements (LSM) than the remaining AATD patients. Among patients with one or two Z alleles, two patients with lung and liver impairment showed the highest concentrations of CP (47.5 µg/mL), followed by those with only liver abnormality (n = 6, CP = 34 µg/mL), only lung (n = 18, CP = 26.5 µg/mL) and no abnormalities (n = 23, CP = 14.3 µg/mL). Differences were highly significant (p = 0.004). CONCLUSIONS: Non-augmented Pi*ZZ and Z-patients with impaired lung function and increased liver stiffness presented higher levels of CP than other clinical phenotypes. Therefore, CP may help to identify patients more at risk of developing lung and liver disease and may provide some insight into the mechanisms of disease.
format Online
Article
Text
id pubmed-8442448
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84424482021-09-15 Association between circulating alpha-1 antitrypsin polymers and lung and liver disease Núñez, Alexa Belmonte, Irene Miranda, Elena Barrecheguren, Miriam Farago, Georgina Loeb, Eduardo Pons, Mònica Rodríguez-Frías, Francisco Gabriel-Medina, Pablo Rodríguez, Esther Genescà, Joan Miravitlles, Marc Esquinas, Cristina Respir Res Research BACKGROUND: Alpha-1 antitrypsin deficiency (AATD) is considered one of the most common genetic diseases and is characterised by the misfolding and polymerisation of the alpha-1 antitrypsin (AAT) protein within hepatocytes. The relevance of circulating polymers (CP) of AAT in the pathogenesis of lung and liver disease is not completely understood. Therefore, the main objective of our study was to determine whether there is an association between the levels of CP of AAT and the severity of lung and liver disease. METHOD: This was a cross-sectional study in patients with different phenotypes of AATD and controls. To quantify CP, a sandwich ELISA was performed using the 2C1 monoclonal antibody against AAT polymers. Sociodemographic data, clinical characteristics, and liver and lung parameters were collected. RESULTS: A cohort of 70 patients was recruited: 32 Pi*ZZ (11 on augmentation therapy); 29 Z-heterozygous; 9 with other genotypes. CP were compared with a control group of 47 individuals (35 Pi*MM and 12 Pi*MS). ZZ patients had the highest concentrations of CP (p < 0.001) followed by Z heterozygous. The control group and patients with Pi*SS and Pi*SI had the lowest CP concentrations. Pi*ZZ also had higher levels of liver stiffness measurements (LSM) than the remaining AATD patients. Among patients with one or two Z alleles, two patients with lung and liver impairment showed the highest concentrations of CP (47.5 µg/mL), followed by those with only liver abnormality (n = 6, CP = 34 µg/mL), only lung (n = 18, CP = 26.5 µg/mL) and no abnormalities (n = 23, CP = 14.3 µg/mL). Differences were highly significant (p = 0.004). CONCLUSIONS: Non-augmented Pi*ZZ and Z-patients with impaired lung function and increased liver stiffness presented higher levels of CP than other clinical phenotypes. Therefore, CP may help to identify patients more at risk of developing lung and liver disease and may provide some insight into the mechanisms of disease. BioMed Central 2021-09-15 2021 /pmc/articles/PMC8442448/ /pubmed/34526035 http://dx.doi.org/10.1186/s12931-021-01842-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Núñez, Alexa
Belmonte, Irene
Miranda, Elena
Barrecheguren, Miriam
Farago, Georgina
Loeb, Eduardo
Pons, Mònica
Rodríguez-Frías, Francisco
Gabriel-Medina, Pablo
Rodríguez, Esther
Genescà, Joan
Miravitlles, Marc
Esquinas, Cristina
Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
title Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
title_full Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
title_fullStr Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
title_full_unstemmed Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
title_short Association between circulating alpha-1 antitrypsin polymers and lung and liver disease
title_sort association between circulating alpha-1 antitrypsin polymers and lung and liver disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442448/
https://www.ncbi.nlm.nih.gov/pubmed/34526035
http://dx.doi.org/10.1186/s12931-021-01842-5
work_keys_str_mv AT nunezalexa associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT belmonteirene associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT mirandaelena associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT barrechegurenmiriam associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT faragogeorgina associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT loebeduardo associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT ponsmonica associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT rodriguezfriasfrancisco associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT gabrielmedinapablo associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT rodriguezesther associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT genescajoan associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT miravitllesmarc associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease
AT esquinascristina associationbetweencirculatingalpha1antitrypsinpolymersandlungandliverdisease